Johannes Bruno Mueller-Reif

Johannes Bruno Mueller-Reif

Auto-generated profile, based on publicly available information

Johannes Bruno Mueller-Reif

Department of Proteomics and Signal Transduction, Max Planck Institute of Biochemistry, Martinsried, Germany

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2020 in Molecular Systems Biology
Verified
Journal Article
Open access
PDF file
JBJakob M Bader
Jakob M Bader
PGPhilipp E Geyer
Philipp E Geyer
JMJohannes B Müller
Johannes B Müller
MSMaximilian T Strauss
Maximilian T Strauss
MKManja Koch
Manja Koch
MMMatthias Mann
Matthias Mann
Neurodegenerative diseases are a growing burden, and there is an urgent need for better biomarkers for diagnosis, prognosis, and treatment efficacy. Structural and functional brain alterations are reflected in the protein composition of cerebrospinal fluid (CSF). Alzheimer's disease (AD) patients have higher CSF levels of tau, but we lack knowledge of systems‐wide changes of CSF protein levels that accompany AD. Here, we present a highly reproducible mass spectrometry (MS)‐based proteomics workflow for the in‐depth analysis of CSF from minimal sample amounts. From three independent studies (197 individuals), we characterize differences in proteins by AD status (> 1,000 proteins, CV < 20%). Proteins with previous links to neurodegeneration such as tau, SOD1, and PARK7 differed most strongly by AD status, providing strong positive controls for our approach. CSF proteome changes in Alzheimer's disease prove to be widespread and often correlated with tau concentrations. Our unbiased screen also reveals a consistent glycolytic signature across our cohorts and a recent study. Machine learning suggests clinical utility of this proteomic signature.

7 July 2021 in EMBO Molecular Medicine
Verified
Journal Article
Open access
PDF file
PGPhilipp E Geyer
Philipp E Geyer
FAFlorian M Arend
Florian M Arend
SDSophia Doll
Sophia Doll
MLMarie‐Luise Louiset
Marie‐Luise Louiset
SWSebastian Virreira Winter
Sebastian Virreira Winter
DTDaniel Teupser
Daniel Teupser
A deeper understanding of COVID‐19 on human molecular pathophysiology is urgently needed as a foundation for the discovery of new biomarkers and therapeutic targets. Here we applied mass spectrometry (MS)‐based proteomics to measure serum proteomes of COVID‐19 patients and symptomatic, but PCR‐negative controls, in a time‐resolved manner. In 262 controls and 458 longitudinal samples of 31 patients, hospitalized for COVID‐19, a remarkable 26% of proteins changed significantly. Bioinformatics analyses revealed co‐regulated groups and shared biological functions. Proteins of the innate immune system such as CRP, SAA1, CD14, LBP, and LGALS3BP decreased early in the time course. Regulators of coagulation (APOH, FN1, HRG, KNG1, PLG) and lipid homeostasis (APOA1, APOC1, APOC2, APOC3, PON1) increased over the course of the disease. A global correlation map provides a system‐wide functional association between proteins, biological processes, and clinical chemistry parameters. Importantly, five SARS‐CoV‐2 immunoassays against antibodies revealed excellent correlations with an extensive range of immunoglobulin regions, which were quantified by MS‐based proteomics. The high‐resolution profile of all immunoglobulin regions showed individual‐specific differences and commonalities of potential pathophysiological relevance.

14 April 2023 in Science
Verified
Journal Article
Closed access
MTManuela Thienel
Manuela Thienel
JMJohannes B. Müller-Reif
Johannes B. Müller-Reif
ZZZhe Zhang
Zhe Zhang
VEVincent Ehreiser
Vincent Ehreiser
JHJudith Huth
Judith Huth
TPTobias Petzold
Tobias Petzold
Venous thromboembolism (VTE) comprising deep venous thrombosis and pulmonary embolism is a major cause of morbidity and mortality. Short-term immobility-related conditions are a major risk factor for the development of VTE. Paradoxically, long-term immobilized free-ranging hibernating brown bears and paralyzed spinal cord injury (SCI) patients are protected from VTE. We aimed to identify mechanisms of immobility-associated VTE protection in a cross-species approach. Mass spectrometry–based proteomics revealed an antithrombotic signature in platelets of hibernating brown bears with heat shock protein 47 (HSP47) as the most substantially reduced protein. HSP47 down-regulation or ablation attenuated immune cell activation and neutrophil extracellular trap formation, contributing to thromboprotection in bears, SCI patients, and mice. This cross-species conserved platelet signature may give rise to antithrombotic therapeutics and prognostic markers beyond immobility-associated VTE.

17 June 2022 in Science Advances
Verified
Journal Article
Open access
PMPavlína Miklánková
Pavlína Miklánková
ELEric Linster
Eric Linster
JBJean-Baptiste Boyer
Jean-Baptiste Boyer
JWJonas Weidenhausen
Jonas Weidenhausen
JMJohannes Mueller
Johannes Mueller
MWMarkus Wirtz
Markus Wirtz
In humans, the Huntingtin yeast partner K (HYPK) binds to the ribosome-associated N α -acetyltransferase A (NatA) complex that acetylates ~40% of the proteome in humans and Arabidopsis thaliana . However, the relevance of Hs HYPK for determining the human N-acetylome is unclear. Here, we identify the At HYPK protein as the first in vivo regulator of NatA activity in plants . At HYPK physically interacts with the ribosome-anchoring subunit of NatA and promotes N α -terminal acetylation of diverse NatA substrates. Loss-of- At HYPK mutants are remarkably resistant to drought stress and strongly resemble the phenotype of NatA-depleted plants. The ectopic expression of Hs HYPK rescues this phenotype. Combined transcriptomics, proteomics, and N-terminomics unravel that HYPK impairs plant metabolism and development, predominantly by regulating NatA activity. We demonstrate that HYPK is a critical regulator of global proteostasis by facilitating masking of the recently identified nonAc-X 2 /N-degron. This N-degron targets many nonacetylated NatA substrates for degradation by the ubiquitin-proteasome system.

12 September 2025 in EMBO Molecular Medicine
Verified
Journal Article
Open access
KKKathrin Korff
Kathrin Korff
JMJohannes B Müller-Reif
Johannes B Müller-Reif
DFDorothea Fichtl
Dorothea Fichtl
VAVincent Albrecht
Vincent Albrecht
ASAlicia-Sophie Schebesta
Alicia-Sophie Schebesta
PGPhilipp E Geyer
Philipp E Geyer
Bead-based enrichment is a promising strategy to improve depth in plasma proteomics by overcoming the dynamic range barrier. However, its robustness against pre-analytical variation has not been sufficiently characterized. Here, we systematically evaluate five plasma proteomics workflows, including three bead-based methods, a neat workflow, and a precipitation protocol using spike-ins of low-abundance proteins and defined cellular contaminants. We find that bead-based approaches enhance detection of low-abundance proteins but can be highly susceptible to systematic bias from platelet and PBMC contamination. This can inflate results by thousands of proteins, potentially explaining some of the high literature-reported numbers. A perchloric acid-based workflow shows resistance to erythrocyte and platelet-derived contamination. We investigate how centrifugation conditions, anticoagulant choice, and buffer-bead combinations modulate contamination profiles and demonstrate that bias can be mitigated by optimized sample handling. Altogether, we identify more than 13,000 different protein groups, including cellular components from the circulating proteome. Our results provide a quantitative framework for assessing workflow performance under variable sample quality and offer guidance for both biomarker discovery and quality control in clinical proteomics studies.

21 April 2021 in Angewandte Chemie International Edition
Verified
Journal Article
Open access
PDF file
LVLiudmila Voronina
Liudmila Voronina
CLCristina Leonardo
Cristina Leonardo
JMJohannes B. Mueller‐Reif
Johannes B. Mueller‐Reif
PGPhilipp E. Geyer
Philipp E. Geyer
MHMarinus Huber
Marinus Huber
MŽMihaela Žigman
Mihaela Žigman
Infrared spectroscopy of liquid biopsies is a time‐ and cost‐effective approach that may advance biomedical diagnostics. However, the molecular nature of disease‐related changes of infrared molecular fingerprints (IMFs) remains poorly understood, impeding the method's applicability. Here we probe 148 human blood sera and reveal the origin of the variations in their IMFs. To that end, we supplemented infrared spectroscopy with biochemical fractionation and proteomic profiling, providing molecular information about serum composition. Using lung cancer as an example of a medical condition, we demonstrate that the disease‐related differences in IMFs are dominated by contributions from twelve highly abundant proteins—that, if used as a pattern, may be instrumental for detecting malignancy. Tying proteomic to spectral information and machine learning advances our understanding of the infrared spectra of liquid biopsies, a framework that could be applied to probing of any disease.